The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Interchangeable Biosimilar Humira Market Research Report 2025
Synopsis
Global Interchangeable Biosimilar Humira market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Interchangeable Biosimilar Humira market research.
Key manufacturers engaged in the Interchangeable Biosimilar Humira industry include Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc. and AbbVie Inc., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Interchangeable Biosimilar Humira were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Interchangeable Biosimilar Humira market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Interchangeable Biosimilar Humira market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Samsung Bioepis Co., Ltd.
Sandoz International GmbH (Novartis AG)
Mylan N.V.
Boehringer Ingelheim International GmbH
Pfizer Inc.
Fresenius Kabi AG
Coherus BioSciences, Inc.
Biogen Inc.
AbbVie Inc.
Celltrion Inc.
Amneal Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc.
Merck & Co., Inc.
Viatris Inc.imilar
Amgen Inc.
Segment by Type
Subcutaneous (SC) Injection
Intravenous (IV) Infusion
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Interchangeable Biosimilar Humira report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Interchangeable Biosimilar Humira market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Interchangeable Biosimilar Humira market research.
Key manufacturers engaged in the Interchangeable Biosimilar Humira industry include Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc. and AbbVie Inc., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Interchangeable Biosimilar Humira were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Interchangeable Biosimilar Humira market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Interchangeable Biosimilar Humira market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Samsung Bioepis Co., Ltd.
Sandoz International GmbH (Novartis AG)
Mylan N.V.
Boehringer Ingelheim International GmbH
Pfizer Inc.
Fresenius Kabi AG
Coherus BioSciences, Inc.
Biogen Inc.
AbbVie Inc.
Celltrion Inc.
Amneal Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc.
Merck & Co., Inc.
Viatris Inc.imilar
Amgen Inc.
Segment by Type
Subcutaneous (SC) Injection
Intravenous (IV) Infusion
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Interchangeable Biosimilar Humira report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Interchangeable Biosimilar Humira Market Overview
1.1 Product Overview and Scope of Interchangeable Biosimilar Humira
1.2 Interchangeable Biosimilar Humira Segment by Type
1.2.1 Global Interchangeable Biosimilar Humira Market Value Comparison by Type (2023-2029)
1.2.2 Subcutaneous (SC) Injection
1.2.3 Intravenous (IV) Infusion
1.3 Interchangeable Biosimilar Humira Segment by Application
1.3.1 Global Interchangeable Biosimilar Humira Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Interchangeable Biosimilar Humira Market Size Estimates and Forecasts
1.4.1 Global Interchangeable Biosimilar Humira Revenue 2018-2029
1.4.2 Global Interchangeable Biosimilar Humira Sales 2018-2029
1.4.3 Global Interchangeable Biosimilar Humira Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Interchangeable Biosimilar Humira Market Competition by Manufacturers
2.1 Global Interchangeable Biosimilar Humira Sales Market Share by Manufacturers (2018-2023)
2.2 Global Interchangeable Biosimilar Humira Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Interchangeable Biosimilar Humira Average Price by Manufacturers (2018-2023)
2.4 Global Interchangeable Biosimilar Humira Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Interchangeable Biosimilar Humira, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Interchangeable Biosimilar Humira, Product Type & Application
2.7 Interchangeable Biosimilar Humira Market Competitive Situation and Trends
2.7.1 Interchangeable Biosimilar Humira Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Interchangeable Biosimilar Humira Players Market Share by Revenue
2.7.3 Global Interchangeable Biosimilar Humira Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Interchangeable Biosimilar Humira Retrospective Market Scenario by Region
3.1 Global Interchangeable Biosimilar Humira Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Interchangeable Biosimilar Humira Global Interchangeable Biosimilar Humira Sales by Region: 2018-2029
3.2.1 Global Interchangeable Biosimilar Humira Sales by Region: 2018-2023
3.2.2 Global Interchangeable Biosimilar Humira Sales by Region: 2024-2029
3.3 Global Interchangeable Biosimilar Humira Global Interchangeable Biosimilar Humira Revenue by Region: 2018-2029
3.3.1 Global Interchangeable Biosimilar Humira Revenue by Region: 2018-2023
3.3.2 Global Interchangeable Biosimilar Humira Revenue by Region: 2024-2029
3.4 North America Interchangeable Biosimilar Humira Market Facts & Figures by Country
3.4.1 North America Interchangeable Biosimilar Humira Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Interchangeable Biosimilar Humira Sales by Country (2018-2029)
3.4.3 North America Interchangeable Biosimilar Humira Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Interchangeable Biosimilar Humira Market Facts & Figures by Country
3.5.1 Europe Interchangeable Biosimilar Humira Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Interchangeable Biosimilar Humira Sales by Country (2018-2029)
3.5.3 Europe Interchangeable Biosimilar Humira Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Interchangeable Biosimilar Humira Market Facts & Figures by Country
3.6.1 Asia Pacific Interchangeable Biosimilar Humira Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Interchangeable Biosimilar Humira Sales by Country (2018-2029)
3.6.3 Asia Pacific Interchangeable Biosimilar Humira Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Interchangeable Biosimilar Humira Market Facts & Figures by Country
3.7.1 Latin America Interchangeable Biosimilar Humira Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Interchangeable Biosimilar Humira Sales by Country (2018-2029)
3.7.3 Latin America Interchangeable Biosimilar Humira Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Interchangeable Biosimilar Humira Market Facts & Figures by Country
3.8.1 Middle East and Africa Interchangeable Biosimilar Humira Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Interchangeable Biosimilar Humira Sales by Country (2018-2029)
3.8.3 Middle East and Africa Interchangeable Biosimilar Humira Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Interchangeable Biosimilar Humira Sales by Type (2018-2029)
4.1.1 Global Interchangeable Biosimilar Humira Sales by Type (2018-2023)
4.1.2 Global Interchangeable Biosimilar Humira Sales by Type (2024-2029)
4.1.3 Global Interchangeable Biosimilar Humira Sales Market Share by Type (2018-2029)
4.2 Global Interchangeable Biosimilar Humira Revenue by Type (2018-2029)
4.2.1 Global Interchangeable Biosimilar Humira Revenue by Type (2018-2023)
4.2.2 Global Interchangeable Biosimilar Humira Revenue by Type (2024-2029)
4.2.3 Global Interchangeable Biosimilar Humira Revenue Market Share by Type (2018-2029)
4.3 Global Interchangeable Biosimilar Humira Price by Type (2018-2029)
5 Segment by Application
5.1 Global Interchangeable Biosimilar Humira Sales by Application (2018-2029)
5.1.1 Global Interchangeable Biosimilar Humira Sales by Application (2018-2023)
5.1.2 Global Interchangeable Biosimilar Humira Sales by Application (2024-2029)
5.1.3 Global Interchangeable Biosimilar Humira Sales Market Share by Application (2018-2029)
5.2 Global Interchangeable Biosimilar Humira Revenue by Application (2018-2029)
5.2.1 Global Interchangeable Biosimilar Humira Revenue by Application (2018-2023)
5.2.2 Global Interchangeable Biosimilar Humira Revenue by Application (2024-2029)
5.2.3 Global Interchangeable Biosimilar Humira Revenue Market Share by Application (2018-2029)
5.3 Global Interchangeable Biosimilar Humira Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Samsung Bioepis Co., Ltd.
6.1.1 Samsung Bioepis Co., Ltd. Corporation Information
6.1.2 Samsung Bioepis Co., Ltd. Description and Business Overview
6.1.3 Samsung Bioepis Co., Ltd. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Samsung Bioepis Co., Ltd. Interchangeable Biosimilar Humira Product Portfolio
6.1.5 Samsung Bioepis Co., Ltd. Recent Developments/Updates
6.2 Sandoz International GmbH (Novartis AG)
6.2.1 Sandoz International GmbH (Novartis AG) Corporation Information
6.2.2 Sandoz International GmbH (Novartis AG) Description and Business Overview
6.2.3 Sandoz International GmbH (Novartis AG) Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Sandoz International GmbH (Novartis AG) Interchangeable Biosimilar Humira Product Portfolio
6.2.5 Sandoz International GmbH (Novartis AG) Recent Developments/Updates
6.3 Mylan N.V.
6.3.1 Mylan N.V. Corporation Information
6.3.2 Mylan N.V. Description and Business Overview
6.3.3 Mylan N.V. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Mylan N.V. Interchangeable Biosimilar Humira Product Portfolio
6.3.5 Mylan N.V. Recent Developments/Updates
6.4 Boehringer Ingelheim International GmbH
6.4.1 Boehringer Ingelheim International GmbH Corporation Information
6.4.2 Boehringer Ingelheim International GmbH Description and Business Overview
6.4.3 Boehringer Ingelheim International GmbH Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Boehringer Ingelheim International GmbH Interchangeable Biosimilar Humira Product Portfolio
6.4.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
6.5 Pfizer Inc.
6.5.1 Pfizer Inc. Corporation Information
6.5.2 Pfizer Inc. Description and Business Overview
6.5.3 Pfizer Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Inc. Interchangeable Biosimilar Humira Product Portfolio
6.5.5 Pfizer Inc. Recent Developments/Updates
6.6 Fresenius Kabi AG
6.6.1 Fresenius Kabi AG Corporation Information
6.6.2 Fresenius Kabi AG Description and Business Overview
6.6.3 Fresenius Kabi AG Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Fresenius Kabi AG Interchangeable Biosimilar Humira Product Portfolio
6.6.5 Fresenius Kabi AG Recent Developments/Updates
6.7 Coherus BioSciences, Inc.
6.6.1 Coherus BioSciences, Inc. Corporation Information
6.6.2 Coherus BioSciences, Inc. Description and Business Overview
6.6.3 Coherus BioSciences, Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Coherus BioSciences, Inc. Interchangeable Biosimilar Humira Product Portfolio
6.7.5 Coherus BioSciences, Inc. Recent Developments/Updates
6.8 Biogen Inc.
6.8.1 Biogen Inc. Corporation Information
6.8.2 Biogen Inc. Description and Business Overview
6.8.3 Biogen Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Biogen Inc. Interchangeable Biosimilar Humira Product Portfolio
6.8.5 Biogen Inc. Recent Developments/Updates
6.9 AbbVie Inc.
6.9.1 AbbVie Inc. Corporation Information
6.9.2 AbbVie Inc. Description and Business Overview
6.9.3 AbbVie Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AbbVie Inc. Interchangeable Biosimilar Humira Product Portfolio
6.9.5 AbbVie Inc. Recent Developments/Updates
6.10 Celltrion Inc.
6.10.1 Celltrion Inc. Corporation Information
6.10.2 Celltrion Inc. Description and Business Overview
6.10.3 Celltrion Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Celltrion Inc. Interchangeable Biosimilar Humira Product Portfolio
6.10.5 Celltrion Inc. Recent Developments/Updates
6.11 Amneal Pharmaceuticals, Inc.
6.11.1 Amneal Pharmaceuticals, Inc. Corporation Information
6.11.2 Amneal Pharmaceuticals, Inc. Interchangeable Biosimilar Humira Description and Business Overview
6.11.3 Amneal Pharmaceuticals, Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Amneal Pharmaceuticals, Inc. Interchangeable Biosimilar Humira Product Portfolio
6.11.5 Amneal Pharmaceuticals, Inc. Recent Developments/Updates
6.12 Lupin Pharmaceuticals, Inc.
6.12.1 Lupin Pharmaceuticals, Inc. Corporation Information
6.12.2 Lupin Pharmaceuticals, Inc. Interchangeable Biosimilar Humira Description and Business Overview
6.12.3 Lupin Pharmaceuticals, Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Lupin Pharmaceuticals, Inc. Interchangeable Biosimilar Humira Product Portfolio
6.12.5 Lupin Pharmaceuticals, Inc. Recent Developments/Updates
6.13 Merck & Co., Inc.
6.13.1 Merck & Co., Inc. Corporation Information
6.13.2 Merck & Co., Inc. Interchangeable Biosimilar Humira Description and Business Overview
6.13.3 Merck & Co., Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Merck & Co., Inc. Interchangeable Biosimilar Humira Product Portfolio
6.13.5 Merck & Co., Inc. Recent Developments/Updates
6.14 Viatris Inc.imilar
6.14.1 Viatris Inc.imilar Corporation Information
6.14.2 Viatris Inc.imilar Interchangeable Biosimilar Humira Description and Business Overview
6.14.3 Viatris Inc.imilar Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Viatris Inc.imilar Interchangeable Biosimilar Humira Product Portfolio
6.14.5 Viatris Inc.imilar Recent Developments/Updates
6.15 Amgen Inc.
6.15.1 Amgen Inc. Corporation Information
6.15.2 Amgen Inc. Interchangeable Biosimilar Humira Description and Business Overview
6.15.3 Amgen Inc. Interchangeable Biosimilar Humira Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Amgen Inc. Interchangeable Biosimilar Humira Product Portfolio
6.15.5 Amgen Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Interchangeable Biosimilar Humira Industry Chain Analysis
7.2 Interchangeable Biosimilar Humira Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Interchangeable Biosimilar Humira Production Mode & Process
7.4 Interchangeable Biosimilar Humira Sales and Marketing
7.4.1 Interchangeable Biosimilar Humira Sales Channels
7.4.2 Interchangeable Biosimilar Humira Distributors
7.5 Interchangeable Biosimilar Humira Customers
8 Interchangeable Biosimilar Humira Market Dynamics
8.1 Interchangeable Biosimilar Humira Industry Trends
8.2 Interchangeable Biosimilar Humira Market Drivers
8.3 Interchangeable Biosimilar Humira Market Challenges
8.4 Interchangeable Biosimilar Humira Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
